News

RPI-78M is ReceptoPharm’s drug candidate for the treatment of autoimmune and neurological disorders and RPI-MN is its leading antiviral drug candidate. Paul Reid, CEO of ReceptoPharm, said: “This

According to the news source, GlaxoSmithKline (GSK) is proposing a new ‘price-volume’ deal to address the concerns of the National Institute for Health and Clinical Excellence (NICE), the

Under the terms of this agreement with Harvard, Oxford Nanopore has exclusive rights to develop and commercialize a number of nanopore technological breakthroughs developed in the laboratories of

The study achieved its primary endpoint. Heplisav is being jointly developed by Dynavax and Merck for use in adults and in patients with end stage renal disease. This

The specific patent, vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be

For the six months ended June 30, 2008, Acadia reported a net loss of $34.7 million, or $0.94 per common share, compared to a net loss of $23.3

The company has appointed Sigurdur Oli Olafsson, former deputy CEO of the company, as the new CEO. Mr Olafsson joined Actavis in 2003, after working for Pfizer UK

As previously reported for Cohorts 1 and 2 of this study, R7128 has demonstrated potent short-term antiviral activity and was generally safe and well tolerated at doses of

The Medicines Company expects to start Phase I clinical testing of CU-2010 in 2008. This acquisition is said to give The Medicines Company an integrated development capability around